Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Earnings
  • News

Spero Therapeutics Q3 EPS $(0.33) Misses $(0.30) Estimate, Sales $2.01M Miss $5.42M Estimate

By Michael Horton
Today, 3:34 AM
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 52.86 percent increase over losses of $(0.70) per share from

SPRO

Read More
17 minute read
  • Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights
Today, 3:34 AM
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

Read More
3 minute read
  • Broad U.S. Equity ETFs
  • ETFs
  • Exclusives
  • Penny Stocks
  • Small Cap
  • Tech
  • Top Stories
  • Trading Ideas

EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?

By Chris Katje
Today, 3:34 AM
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

AAPL

Read More
1 minute read
  • Events
  • News

Spero Therapeutics To Host Virtual R&D Event On Non-Tuberculous Mycobacterial Pulmonary Disease And The SPR720 Program October 6

By Benzinga Newsdesk
Today, 3:34 AM
Event is taking place on Thursday, October 6th at 11:30 a.m. ET   Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical

SPRO

Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Penny Stocks
  • Price Target
  • Small Cap
  • Trading Ideas

This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike

By Lisa Levin
Today, 3:34 AM
UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.

BALL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Lowers Price Target to $6

By Benzinga Newsdesk
Today, 3:34 AM
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and lowers the price target from $7 to $6.

SPRO

Read More
2 minute read
  • Penny Stocks
  • Short Ideas
  • Trading Ideas

Short Volatility Alert: Spero Therapeutics, Inc.

By Christopher Sappo
Today, 3:34 AM
On Thursday, shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) experienced volatile short activity. After the activity, the stock price went up +168.29% to $2.20. The overall sentiment for SPRO has been Bearish.

SPRO

Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Penny Stocks
  • Price Target
  • Small Cap
  • Trading Ideas

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

By Lisa Levin
Today, 3:34 AM
Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero Therapeutics shares rose 7.3% to $2.37 on Friday.

ACN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Upgrades

Evercore ISI Group Upgrades Spero Therapeutics to Outperform, Raises Price Target to $8

By Benzinga Newsdesk
Today, 3:34 AM
Evercore ISI Group analyst Josh Schimmer upgrades Spero Therapeutics (NASDAQ:SPRO) from In-Line to Outperform and raises the price target from $2 to $8.

SPRO

Read More
6 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday

By Lisa Levin
Today, 3:34 AM
Gainers

$APE

Posts navigation

1 2 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service